Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  Mayne Pharma Group Limited    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 35% by 2023.
Weaknesses
  • Low profitability weakens the company.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
MAYNE PHARMA GROUP LIMITED0.00%458
MERCK KGAA6.02%78 134
ZHANGZHOU PIENTZEHUANG PHAR..5.98%26 625
KYOWA KIRIN CO., LTD.1.49%14 610
BETTA PHARMACEUTICALS CO., ..17.07%7 873
YUHAN CORPORATION-3.33%4 063
RECIPHARM AB (PUBL)2.10%2 693
SUPERNUS PHARMACEUTICALS, I..16.14%1 539
INDIVIOR9.56%1 187
CALLIDITAS THERAPEUTICS AB ..-5.44%786
DONG-A ST CO., LTD.-4.18%645
NICHI-IKO PHARMACEUTICAL CO..1.33%613
KNIGHT THERAPEUTICS INC.4.30%569
CHONG KUN DANG HOLDINGS COR..-12.94%506
THERAPEUTICSMD, INC.14.05%409
ISOFOL MEDICAL AB (PUBL)6.43%296
-
More Results
Financials
Sales 2021 458 M 352 M 352 M
Net income 2021 -9,13 M -7,03 M -7,03 M
Net Debt 2021 255 M 196 M 196 M
P/E ratio 2021 -56,0x
Yield 2021 -
Capitalization 579 M 445 M 446 M
EV / Sales 2021 1,82x
EV / Sales 2022 1,48x
Nbr of Employees 967
Free-Float 81,1%
Upcoming event on MAYNE PHARMA GROUP LIMITED
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes